Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults
Stacie M. Jones,Scott H. Sicherer,A. Wesley Burks,Donald Y.M. Leung,Robert Lindblad,Peter Dawson,Alice K. Henning,M. Cecilia Berin,David Y. Chiang,Brian P. Vickery,Robbie D. Pesek,Christine B. Cho,Wendy F. Davidson,Marshall Plaut,Hugh A. Sampson,Robert A. Wood +15 more
TLDR
Peanut EPIT administration was safe and associated with a modest treatment response after 52 weeks, with the highest responses among younger children, and when coupled with a high adherence and retention rate and significant changes in immune pathways, supports further investigation of this novel therapy.Abstract:
Background Peanut allergy is common, life-threatening, and without therapeutic options We evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanut for peanut allergy treatment Objective We sought to evaluate the clinical, safety, and immunologic effects of EPIT for the treatment of peanut allergy Methods In this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut allergy (ages 4-25 years) were treated with placebo (n = 25), Viaskin Peanut 100 μg (VP100; n = 24) or Viaskin Peanut 250 μg (VP250; n = 25; DBV Technologies, Montrouge, France) The primary outcome was treatment success after 52 weeks, which was defined as passing a 5044-mg protein oral food challenge or achieving a 10-fold or greater increase in successfully consumed dose from baseline to week 52 Adverse reactions and mechanistic changes were assessed Results At week 52, treatment success was achieved in 3 (12%) placebo-treated participants, 11 (46%) VP100 participants, and 12 (48%) VP250 participants ( P = 005 and P = 003, respectively, compared with placebo; VP100 vs VP250, P = 48) Median change in successfully consumed doses were 0, 43, and 130 mg of protein in the placebo, VP100, and VP250 groups, respectively (placebo vs VP100, P = 014; placebo vs VP250, P = 003) Treatment success was higher among younger children ( P = 03; age, 4-11 vs >11 years) Overall, 144% of placebo doses and 798% of VP100 and VP250 doses resulted in reactions, predominantly local patch-site and mild reactions ( P = 003) Increases in peanut-specific IgG 4 levels and IgG 4 /IgE ratios were observed in peanut EPIT-treated participants, along with trends toward reduced basophil activation and peanut-specific T H 2 cytokines Conclusions Peanut EPIT administration was safe and associated with a modest treatment response after 52 weeks, with the highest responses among younger children This, when coupled with a high adherence and retention rate and significant changes in immune pathways, supports further investigation of this novel therapyread more
Citations
More filters
Journal ArticleDOI
Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management.
TL;DR: This review provides general information to serve as a primer for those embarking on understanding food allergy and also details advances and updates in epidemiology, pathogenesis, diagnosis, and treatment that have occurred over the 4 years since the last comprehensive review.
Journal ArticleDOI
EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
Giovanni B. Pajno,Montserrat Fernandez-Rivas,Stefania Arasi,Stefania Arasi,Graham Roberts,Graham Roberts,Graham Roberts,Cezmi A. Akdis,Montserrat Alvaro-Lozano,Kirsten Beyer,Carsten Bindslev-Jensen,Wesley Burks,M. Ebisawa,Philippe Eigenmann,Edward F. Knol,Kari C. Nadeau,Lars K. Poulsen,R. van Ree,Alexandra F. Santos,Alexandra F. Santos,G. Du Toit,G. Du Toit,S. Dhami,Ulugbek Nurmatov,Y Boloh,Mika J. Mäkelä,Liam O'Mahony,Nikolaos G. Papadopoulos,Cansin Sackesen,Ioana Agache,Elizabeth Angier,Susanne Halken,Marek Jutel,Steffen Lau,Oliver Pfaar,Dermot Ryan,Gunter J. Sturm,E-M. Varga,R. G. Van Wijk,Aziz Sheikh,Antonella Muraro +40 more
TL;DR: Patients and their families should be provided with information about the use of FA‐AIT for IgE‐mediated food allergy to allow them to make an informed decision about the therapy.
Iconographies supplémentaires de l'article : Oral peanut immunotherapy in children with peanut anaphylaxis
Katharina Blumchen,Helen Ulbricht,U. Staden,Kerstin Dobberstein,John Beschorner,Lucila Camargo Lopes de Oliveira,Wayne G. Shreffler,Hugh A. Sampson,Bodo Niggemann,Ulrich Wahn,Kirsten Beyer +10 more
TL;DR: In this article, the authors investigated the efficacy and safety of oral immunotherapy (OIT) in peanut allergy and found that OIT appeared to be safe and of some benefit in many patients with peanut allergy.
Journal ArticleDOI
Oral Immunotherapy for Treatment of Egg Allergy in Children
TL;DR: To determine that oral immunotherapy (OIT) to egg is safe and effective to desensitize patients and induce sustained unresponsiveness, a double-blind, randomized placebo-controlled study of 55 children, sensitive to egg, is conducted.
Journal ArticleDOI
Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells
TL;DR: Better understanding of the molecular mechanism governing the generation of Treg and Breg cells during allergen tolerance might well open new avenues for alternative therapeutic interventions in allergic diseases and help better understanding of other immune‐tolerance‐related diseases.
References
More filters
Journal ArticleDOI
Evidence of Desensitization by Sublingual Immunotherapy in Peanut-Allergic Children
Edwin H. Kim,J.A. Bird,Mike Kulis,Susan Laubach,Wayne G. Shreffler,Laurent Pons,Pamela H. Steele,J. Kamilaris,Brian P. Vickery,A.W. Burks +9 more
Journal ArticleDOI
Epicutaneous Immunotherapy (EPIT) Is Effective and Safe to Treat Peanut Allergy: A Multi-National Double-Blind Placebo-Controlled Randomized Phase IIb Trial
Hugh A. Sampson,Wence Agbotounou,Claude Thébault,Ruban Charles,Laurent Martin,William H. Yang,Gordon Sussman,Terri F. Brown-Whitehorn,Kari C. Nadeau,Amarjit Cheema,Stephanie A. Leonard,Jacqueline A. Pongracic,Christine Sauvage,Amal Assa'ad,Frédéric de Blay,J. Andrew Bird,Stephen A. Tilles,Franck Boralevi,Thierry Bourrier,Wayne G. Shreffler,Jacques Hébert,Todd D. Green,Roy Gerth van Wijk,André C. Knulst,Gisèle Kanny,Marek L. Kowalski,Lynda C. Schneider,Pierre Henri Benhamou,Christophe Dupont +28 more
TL;DR: Sampson H.A.H. 3, Sussman G.L.2, Ruban C.C.1, Agbotounou W.K. 2, and Dupont C.2.
Journal ArticleDOI
Epicutaneous Immunotherapy-Induced Regulatory T Cells Could Migrate To More Various Sites Of Allergen Exposure Compared To Sublingual Or Subcutaneous Immunotherapy In Mice Sensitized To Peanut
Vincent Dioszeghy,Lucie Mondoulet,Véronique Dhelft,Mélanie Ligouis,Emilie Puteaux,Camille Plaquet,Christophe Dupont,Pierre Henri Benhamou +7 more
Journal ArticleDOI
High Rate of Sustained Unresponsiveness with Early-Intervention Peanut Oral Immunotherapy
Brian P. Vickery,Ayeshia Beavers,Jelena P. Berglund,Jill P. French,Deanna K. Hamilton,Lauren Herlihy,Edwin H. Kim,Michael D. Kulis,Nicole Szczepanski,Pamela H. Steele,Yamini V. Virkud,Benjamin L. Wright,A. Wesley Burks +12 more
Related Papers (5)
AR101 Oral Immunotherapy for Peanut Allergy
Brian P. Vickery,Andrea Vereda,Thomas B. Casale,Kirsten Beyer,George Du Toit,Jonathan O'b Hourihane,Stacie M. Jones,Stacie M. Jones,Wayne G. Shreffler,Annette Marcantonio,Rezi Zawadzki,Lawrence Sher,W. Carr,Stanley Fineman,Leon Greos,Rima Rachid,M Dolores Ibáñez,Stephen A. Tilles,Amal Assa'ad,Caroline Nilsson,Ned Rupp,Michael J Welch,Gordon Sussman,Sharon Chinthrajah,Katharina Blumchen,Ellen Sher,Jonathan M. Spergel,Frederick E Leickly,Stefan Zielen,Julie Wang,Georgiana M Sanders,Robert A. Wood,Amarjit Cheema,Carsten Bindslev-Jensen,Stephanie A. Leonard,Rita Kachru,Douglas T Johnston,Frank C Hampel,Edwin H. Kim,Aikaterini Anagnostou,Jacqueline A. Pongracic,Moshe Ben-Shoshan,Hemant P Sharma,Allan Stillerman,Hugh H Windom,William H. Yang,Antonella Muraro,José Manuel Zubeldia,Vibha Sharma,Morna J. Dorsey,Hey Chong,Jason A. Ohayon,J. Andrew Bird,Tara F. Carr,Dareen Siri,Montserrat Fernandez-Rivas,David K Jeong,David Fleischer,Jay A. Lieberman,Anthony E.J. Dubois,Marina Tsoumani,Christina E. Ciaccio,Jay M. Portnoy,Lyndon E Mansfield,Stephen B Fritz,Bruce J. Lanser,Jonathan Matz,Hanneke N G Oude Elberink,Pooja Varshney,Stephen G Dilly,Daniel C. Adelman,A. Wesley Burks +71 more
Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
Brian P. Vickery,Amy M. Scurlock,Michael D. Kulis,Pamela H. Steele,J. Kamilaris,Jelena P. Berglund,Caitlin M. Burk,Anne Hiegel,Suzanna K. Carlisle,Lynn Christie,Tamara T. Perry,Robbie D. Pesek,Saira Z Sheikh,Yamini V. Virkud,P. Brian Smith,Mohamed H. Shamji,Stephen R. Durham,Stacie M. Jones,A. Wesley Burks +18 more